Macquarie Group LTD Bristol Myers Squibb CO Transaction History

Macquarie Group LTD

  • $87.4 Billion
  • Q1 2024

A detailed history of Macquarie Group LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Macquarie Group LTD holds 1,512,527 shares of BMY stock, worth $62.8 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,512,527
Previous 1,515,205 0.18%
Holding current value
$62.8 Million
Previous $77.7 Million 5.5%
% of portfolio
0.09%
Previous 0.09%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$47.98 - $54.4 $128,490 - $145,683
-2,678 Reduced 0.18%
1,512,527 $82 Million
Q4 2023

Feb 14, 2024
BUY
$48.48 - $57.85 $2.61 Million - $3.11 Million
53,823 Added 3.68%
1,515,205 $77.7 Million
Q3 2023

Nov 14, 2023
BUY
$57.89 - $64.73 $566,279 - $633,188
9,782 Added 0.67%
1,461,382 $84.8 Million
Q2 2023

Aug 14, 2023
SELL
$63.71 - $70.74 $3.22 Million - $3.58 Million
-50,577 Reduced 3.37%
1,451,600 $92.8 Million
Q1 2023

May 15, 2023
BUY
$65.71 - $74.53 $148,767 - $168,735
2,264 Added 0.15%
1,502,177 $104 Million
Q4 2022

Feb 21, 2023
BUY
$68.48 - $81.09 $1.33 Million - $1.58 Million
19,487 Added 1.32%
1,499,913 $108 Million
Q3 2022

Nov 14, 2022
BUY
$0.13 - $76.84 $1,421 - $840,014
10,932 Added 0.74%
1,480,426 $105 Million
Q2 2022

Aug 15, 2022
SELL
$72.62 - $79.98 $415,967 - $458,125
-5,728 Reduced 0.39%
1,469,494 $113 Million
Q1 2022

May 16, 2022
SELL
$61.48 - $73.72 $11.5 Million - $13.8 Million
-187,541 Reduced 11.28%
1,475,222 $108 Million
Q4 2021

Feb 11, 2022
BUY
$53.63 - $62.52 $221,545 - $258,270
4,131 Added 0.25%
1,662,763 $104 Million
Q3 2021

Nov 12, 2021
BUY
$59.17 - $69.31 $27.2 Million - $31.9 Million
460,092 Added 38.39%
1,658,632 $98.1 Million
Q2 2021

Aug 13, 2021
BUY
$61.91 - $67.42 $6.31 Million - $6.87 Million
101,866 Added 9.29%
1,198,540 $80.1 Million
Q1 2021

May 14, 2021
BUY
$59.34 - $66.74 $31.8 Million - $35.8 Million
535,785 Added 95.52%
1,096,674 $69.2 Million
Q4 2020

Feb 16, 2021
SELL
$57.74 - $65.43 $15.3 Million - $17.4 Million
-265,575 Reduced 32.13%
560,889 $34.8 Million
Q3 2020

Nov 13, 2020
BUY
$57.43 - $63.64 $9.75 Million - $10.8 Million
169,812 Added 25.86%
826,464 $49.8 Million
Q2 2020

Aug 11, 2020
SELL
$54.82 - $64.09 $420,962 - $492,147
-7,679 Reduced 1.16%
656,652 $38.6 Million
Q1 2020

May 15, 2020
SELL
$46.4 - $67.43 $1.32 Million - $1.92 Million
-28,517 Reduced 4.12%
664,331 $37 Million
Q4 2019

Feb 14, 2020
BUY
$49.21 - $64.19 $24.8 Million - $32.3 Million
502,961 Added 264.87%
692,848 $44.5 Million
Q3 2019

Nov 14, 2019
SELL
$42.77 - $50.71 $24,122 - $28,600
-564 Reduced 0.3%
189,887 $9.63 Million
Q2 2019

Aug 14, 2019
BUY
$44.62 - $49.34 $611,606 - $676,303
13,707 Added 7.76%
190,451 $8.64 Million
Q1 2019

May 15, 2019
BUY
$45.12 - $53.8 $48,729 - $58,104
1,080 Added 0.61%
176,744 $8.43 Million
Q4 2018

Feb 15, 2019
SELL
$48.76 - $63.23 $552,743 - $716,775
-11,336 Reduced 6.06%
175,664 $9.13 Million
Q3 2018

Nov 15, 2018
SELL
$55.19 - $62.25 $441,520 - $498,000
-8,000 Reduced 4.1%
187,000 $11.6 Million
Q2 2018

Aug 14, 2018
BUY
$50.53 - $62.98 $65,689 - $81,874
1,300 Added 0.67%
195,000 $10.8 Million
Q1 2018

May 11, 2018
SELL
$59.92 - $68.98 $353,528 - $406,982
-5,900 Reduced 2.96%
193,700 $12.3 Million
Q4 2017

Feb 15, 2018
SELL
$59.94 - $65.35 $2.45 Million - $2.68 Million
-40,934 Reduced 17.02%
199,600 $12.4 Million
Q3 2017

Nov 08, 2017
BUY
$55.23 - $63.74 $13.3 Million - $15.3 Million
240,534
240,534 $15.3 Million

Others Institutions Holding BMY

# of Institutions
2,554
Shares Held
1.49B
Call Options Held
25.9M
Put Options Held
20M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $88.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email